Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.41−0.07 (-14.34%)
Close on Nov 18, 2026Market cap $63.33MP/E –Yield –
Coherus Oncology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Coherus Oncology's revenue for the twelve months ending Jun 30, 2026 was $50.94M, up 61.0% year over year. For fiscal 2025 it was $42.17M, up 59.8% from the year before. Over ten years it grew 3.5% a year on average. The highest annual figure on record is $475.82M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.17M | +59.8% |
| FY2024 | Dec 31, 2024 | $26.39M | -89.7% |
| FY2023 | Dec 31, 2023 | $257.24M | +21.9% |
| FY2022 | Dec 31, 2022 | $211.04M | -35.4% |
| FY2021 | Dec 31, 2021 | $326.55M | -31.4% |
| FY2020 | Dec 31, 2020 | $475.82M | +33.6% |
| FY2019 | Dec 31, 2019 | $356.07M | – |
| FY2018 | Dec 31, 2018 | $0 | -100.0% |
| FY2017 | Dec 31, 2017 | $1.56M | -99.2% |
| FY2016 | Dec 31, 2016 | $190.11M | +532.8% |
| FY2015 | Dec 31, 2015 | $30.04M | -3.4% |
| FY2014 | Dec 31, 2014 | $31.11M | +1030.7% |
| FY2013 | Dec 31, 2013 | $2.75M | +44.9% |
| FY2012 | Dec 31, 2012 | $1.90M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.31M | +39.5% |
| Q1 FY2026 | Mar 31, 2026 | $12.31M | +62.0% |
| Q4 FY2025 | Dec 31, 2025 | $12.75M | +64.9% |
| Q3 FY2025 | Sep 30, 2025 | $11.57M | +91.2% |
| Q2 FY2025 | Jun 30, 2025 | $10.25M | -0.4% |
| Q1 FY2025 | Mar 31, 2025 | $7.60M | +229.2% |
| Q4 FY2024 | Dec 31, 2024 | $7.73M | -91.6% |
| Q3 FY2024 | Sep 30, 2024 | $6.05M | -91.9% |
| Q2 FY2024 | Jun 30, 2024 | $10.30M | -82.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.31M | -92.9% |
| Q4 FY2023 | Dec 31, 2023 | $91.52M | +101.8% |
| Q3 FY2023 | Sep 30, 2023 | $74.57M | +64.2% |
| Q2 FY2023 | Jun 30, 2023 | $58.72M | -2.4% |
| Q1 FY2023 | Mar 31, 2023 | $32.44M | -46.0% |
| Q4 FY2022 | Dec 31, 2022 | $45.35M | -38.2% |
| Q3 FY2022 | Sep 30, 2022 | $45.42M | -44.9% |
| Q2 FY2022 | Jun 30, 2022 | $60.15M | -31.4% |
| Q1 FY2022 | Mar 31, 2022 | $60.12M | -27.6% |
| Q4 FY2021 | Dec 31, 2021 | $73.37M | -33.6% |
| Q3 FY2021 | Sep 30, 2021 | $82.50M | -27.3% |
| Q2 FY2021 | Jun 30, 2021 | $87.64M | -35.4% |
| Q1 FY2021 | Mar 31, 2021 | $83.03M | -28.5% |
| Q4 FY2020 | Dec 31, 2020 | $110.42M | -10.8% |
| Q3 FY2020 | Sep 30, 2020 | $113.55M | +1.7% |
| Q2 FY2020 | Jun 30, 2020 | $135.67M | +62.6% |
| Q1 FY2020 | Mar 31, 2020 | $116.18M | +213.2% |
| Q4 FY2019 | Dec 31, 2019 | $123.86M | – |
| Q3 FY2019 | Sep 30, 2019 | $111.68M | – |
| Q2 FY2019 | Jun 30, 2019 | $83.43M | – |
| Q1 FY2019 | Mar 31, 2019 | $37.10M | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $0 | -100.0% |
| Q4 FY2017 | Dec 31, 2017 | $0 | -100.0% |
| Q3 FY2017 | Sep 30, 2017 | $0 | -100.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $161.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $844.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $162.84M | – |
See a number that looks wrong?